Hannover, Germany – 6 February 2007 – ImVisioN Therapeutics Inc., the Hannover based biopharmaceutical company pioneering intralymphatic immunotherapy, announced today that it has been granted European Patent No. 1408114B1, entitled ‘Modular antigen-transporter-molecules (MAT™-molecules) for modulating immune responses’ by the European Patent Office. At the same time, ImVisioN also announced the EU and Australian patents for the ILIT™ technology had also been granted. The US patent for ILIT was previously licensed from MannKind Corporation. Finally, ImVisioN announced that it obtained an option for a license to a portfolio of patents covering the Fel d1 allergen from cat dander which is the allergen component of ImVisioN’s lead allergy immunotherapy product.
